A meta-analysis of nivolumab (CheckMate 057), pembrolizumab (KEYNOTE-010), and atezolizumab (POPLAR) confirmed that ICIs as a second-line treatment prolonged the overall survival (OS) over docetaxel in wild-type EGFR but not in EGFR-mutant advanced NSCLC patients [8]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.